Canaccord lowered the firm’s price target on Compass Therapeutics (CMPX) to $7 from $13 and keeps a Buy rating on the shares. The firm said Tovecimig+paclitaxel clearly improves progression-free survival vs paclitaxel monotherapy, but 54% crossover confounded any possible overall survival benefit in the ITT population. The active arm did however show numerically superior overall survival to patients that did not crossover, but they doubt the FDA would consider this to be sufficient for full approval.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
- Compass Therapeutics price target lowered to $6 from $12 at Stifel
- Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies
- Leerink says Compass data supports path forward for tovecimig in 2L BTC
- Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC